

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 February 2005 (24.02.2005)

PCT

(110) International Publication Number
WO 2005/017493 A2

(51) International Patent Classification: G01N
(21) International Application Number: PCT/US2004/026434
(22) International Filing Date: 10 August 2004 (10.08.2004)
(23) Filing Language: English
(24) Publication Language: English
(30) Priority Date: 15 August 2003 (15.08.2003) US 62493,323

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, P.O. Box 7929, Philadelphia, PA 19101 (US).

(72) Inventor; and

(73) Inventor/Applicant (for US only): RACUS, Sarah, & SMITHKLINE BEECHAM CORPORATION
[US/US]; 1223 Indiana Trail, Huntville, IL 62521 (US).
SPECTOR, Neil, Leo [US/US]; GlaxoSmithKline, Five
Mason Drive, P.O. Box 13394, Research Triangle Park,
NC 27709 (US).

(74) Agent: LEVY, David, J.; GlaxoSmithKline, Five Mason
Drive, P.O. Box 13394, Research Triangle Park, NC 27709
(US).

(54) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GR, GM, GU, HT, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LI, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TD,
TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(54) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasia (AM, AZ, BY, EG, GZ, MD, RU, TJ, TD),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TO).

Publication:

— without international search report and to be republished
upon receipt of that report


For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(52) Title: BIOMARKERS IN CANCER


p-Tyr/erbB-2



p-Erk1/2



Erk1/2



V 0.5 2.5 5

(57) Abstract: Biomarkers may be used in the treatment of cancer, and as an aid in clinical decision making regarding which anti-
cancer therapy to use in a particular patient. Described herein are methods of assessing whether a subject with a solid tumor is
suitable for treatment with a dual EGFR/erbB2 tyrosine kinase inhibitor, by assessing the relative localization of pERK or pAKT in
tumor cells, and/or assessing pre-treatment tumor cell levels of ErbB2.

BEST AVAILABLE COPY

BEST AVAILABLE COPY